I-Mab Advances AstraZeneca-Partnered CD-47 Candidate
December 04, 2020 at 04:56 AM EST
Shanghai 's I-Mab reported clinical trial progress for its "highly differentiated" anti-CD47 mAb lemzoparlimab. In September, I-Mab out-licensed ex-China rights for the candidate to AstraZeneca in a deal worth up to $2 billion. In a US trial, lemzoparlimab is being tested with Rituxan® for non-Hodgkin lymphoma and with Keytruda® in solid tumors. The NHL trial is being conducted in the US and China , while the solid tumor trial is a China-only study. More details.... Stock Symbols: (NSDQ: IMAB) (NYSE: AZN) Share this with colleagues: // //